Table 1. Results of competition binding ELISAs for MAb epitope studies.
unlabelled mAbs | HRP-conjugated mAbs | |||||||
8E10-HRP | 1F4-HRP | 2B2-HRP | 5G10-HRP | 2H12-HRP | 2F4-HRP | 8D1-HRP | ||
Group 1 | 8E10 | 9 | 7 | 8 | 90 | 92 | 90 | 92 |
1F4 | 8 | 5 | 7 | 88 | 91 | 91 | 93 | |
2B2 | 6 | 9 | 8 | 92 | 88 | 95 | 93 | |
Group 2 | 5G10 | 91 | 90 | 85 | 5 | 6 | 78 | 80 |
2H12 | 87 | 90 | 89 | 7 | 4 | 81 | 79 | |
Group 3 | 2F4 | 90 | 87 | 91 | 82 | 79 | 3 | 5 |
8D1 | 88 | 93 | 87 | 80 | 78 | 6 | 4 | |
PBS | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Results were expressed as percent binding of HRP-conjugated mAbs. The amount of binding obtained in the absence of unlabeled antibody was set at 100% for each HRP conjugated mAb. First column indicates the group assignments of mAbs based on competition binding assay. mAbs binding to overlapping epitopes are grouped together, while non-competing mAbs are grouped individually.